At 8 a.m. this morning, $NTLA will be hosting an Investor Relations event, where we’ll discuss our recent interim clinical results from our Phase 1 study for #ATTR. Click here to register for the webcast: https://t.co/f6xExVHIJt #amyloidosis #genomeediting #CRISPR https://t.co/YnWNJC4lz1